Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

South Africa Ups The Ante On COVID-19 Vaccines IP Waiver

UK Is Under Pressure To Back The Proposal

Executive Summary

With the COVID-19 situation spiraling out of control in India, Brazil and other parts of the world, calls for the suspension of IP protections on coronavirus vaccines are growing louder. But the R&D based pharmaceutical industry insists a waiver is not the way forward.

You may also be interested in...



Biden To Give Away 10% Of US COVID-19 Vaccine Supply As He Mulls Call For Patent Waiver

President Biden announced plans to increase vaccination in the US as members of Congress and industry press the administration to take steps to expand global access to COVID-19 vaccines. BIO proposes an alternative to the TRIPS waiver that would expedite export of raw materials and manufacturing supplies.

Of Patents And Production: Industry-White House Row Over Vaccine Exports Highlights Policy Divide

BIO chief calls US Defense Production Act ‘misguided’ as India seeks more COVID vaccines; America will donate AstraZeneca vaccine – just as soon as the FDA determines it was adequately manufactured.

Coronavirus Notebook: WHO’s Plan For Vaccine Manufacturing In Lower-Income Countries, UK Urged To Back IP Waiver

The UK’s independent vaccines committee has finalized its recommendations for the second phase of the COVID-19 vaccination program, and safety issues with several vaccines are still hitting the headlines.

Topics

Related Companies

UsernamePublicRestriction

Register

PS144221

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel